ClinicalTrials.gg
CompletedNCT06214052Updated Jun 29, 2025Results posted

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

A Phase 2 interventional study of VH4524184 and Matching Placebo in HIV Infections, sponsored by ViiV Healthcare. Completed at 17 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
176th of 210
22 · median 82
Started
2024
with 10 others
Phase 2
48 of 266
2 open now
Registered
244th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 176th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 48 in phase 2, and was the 244th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.

03

Conditions studied

  • HIV Infections

Keywords

  • Human immunodeficiency virus
  • Proof of concept
  • Antiviral Agents
  • Virus Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 65 years of age inclusive at the time of signing the .
  • Participants who are overtly healthy (other than infection) as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Positive HIV antibody test
  • Documented HIV infection and Screening plasma HIV-1 RNA ≥ 3,000 copies/mL. A single repeat of this test is allowed within a single Screening period to determine eligibility.
  • Screening ≥200 cells/mm3
  • Treatment-naïve: No antiretrovirals (ARVs, in combination or monotherapy) received after the diagnosis of HIV-1 infection.
  • HIV Pre-exposure or post-exposure prophylaxis: No prior use of any INSTI (including cabotegravir) for HIV pre-exposure or post-exposure prophylaxis.
  • Body weight ≥50.0 kg (110 lbs.) for men and ≥45.0 kg (99 lbs) for women and within the range 18.5-31.0 kg/m2 (inclusive - applies to males and females).
  • A participant of must have a negative serum hCG test at screening, and negative urine hCG test at Day 1, before the first dose of study intervention.
  • If a urine test cannot be confirmed as negative (e.g. ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease risk for inclusion of a female with an early undetected pregnancy.
  • Capable of giving signed informed consent
  • Participant must be willing and able to start standard-of-care ART as selected with the investigator on Study Day 10.

Exclusion criteria

Exclusion Criteria:

  • Participants with primary infection. Any evidence of an active CDC Stage 3 disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy during the study. Untreated syphilis infection [positive RPR at screen] without documentation of treatment. Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; or other localized malignancies
  • Any pre-existing physical or mental condition which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Any history of significant underlying psychiatric disorder, or a clinical assessment of suicidality based on the responses on the eCSSRS.
  • Any history of major depressive disorder with or without suicidal features, or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long syndrome or sudden cardiac death. Treatment with immunomodulating agents (such as systemic , interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of study drug administration.
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing. Specific medications listed in Section 6.9.1 may be allowed.
  • Participants who require concomitant medications known to be associated with a prolonged QTc.
  • Participants receiving any protocol-prohibited medication(s) and who are unwilling or unable to switch to an alternate medication).
  • The participant has ever received an HIV vaccine (immunotherapeutic or immunomodulatory).
  • Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
  • Participation in the study would result in donation of blood in excess of 500 mL within 56 days.
  • Exposure to more than four new investigational drugs or vaccines within 12 months prior to the first dosing day.
  • Current enrollment or past participation within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.

Diagnostic Assessments

  • Presence of or HBcAb at screening
  • Positive antibody test result at Screening
  • Positive Hepatitis C RNA test result at Screening.
  • () of \< 60 mL/min/1.73 m2 using CKD-EPI equation (2021).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    VH4524184 Dose 1

    Participants received VH4524184, administered as Dose 1 (low dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label standard-of-care (SOC) antiretroviral therapy (ART), which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.

    Drug: VH4524184 · Drug: Antiretroviral therapy

  • Experimental
    VH4524184 Dose 2

    Participants received VH4524184, administered as Dose 2 (medium dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.

    Drug: VH4524184 · Drug: Antiretroviral therapy

  • Experimental
    VH4524184 Dose 3

    Participants received VH4524184, administered as Dose 3 (high dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.

    Drug: VH4524184 · Drug: Antiretroviral therapy

  • Placebo comparator
    Placebo

    Participants received matching Placebo to the study intervention on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.

    Drug: Matching Placebo · Drug: Antiretroviral therapy

Interventions

  • VH4524184 was administered as tablets orally at Day 1.

  • DrugMatching Placebo

    VH4524184 Matching Placebo was administered as tablets orally at Day 1.

  • DrugAntiretroviral therapy

    Antiretroviral therapy was administered as available and as per investigator's recommendation.

06

What researchers measure

Primary outcomes

  1. Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)

    Plasma samples were collected for the quantitative analysis of plasma HIV-1 RNA. The maximum change from baseline was calculated by determining the largest change from baseline value across all assessment timepoints during the monotherapy period. This is identified by subtracting the lowest post-dose visit value up to Day 10 (inclusive) from the baseline value. The baseline was defined as the most recent pre-dose assessment with a valid, non-missing value, including measurements from any unscheduled visits.

    Time frame: At Day 10

Secondary outcomes

  1. Monotherapy and Follow-up: Number of Participants With Any Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Any AEs = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 to Day 38

  2. Monotherapy and Follow-up: Number of Participants With AEs by Severity

    The severity was assessed using The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening and Grade 5 = Death.

    Time frame: Day 1 to Day 38

  3. Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation

    Time frame: Day 1 to Day 7

  4. Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)

    Blood samples were collected at the indicated timepoints.

    Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38

  5. Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Bilirubin

    Blood samples were collected at the indicated timepoints.

    Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38

  6. Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Protein

    Blood samples were collected at the indicated timepoints.

    Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38

  7. Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: ALT, AST, ALP, Bilirubin

    Liver panel parameters assessed were: ALT, AST, ALP, bilirubin. The parameters were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in grade relative to baseline grade.

    Time frame: From Baseline (Day 1) and up to Day 38

  8. Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: Protein

    Participants are categorized based on changes in their liver panel laboratory parameters (protein) to 'Low,' 'Normal,' or 'High,' unless there is no change in their initial category. Participants whose lab values remain unchanged (e.g., 'High' to 'High') or whose values return to normal are recorded in the 'To Normal or No Change' category. Participants may be counted in both the 'To Low' and 'To High' categories if their values fluctuate between these states. As a result, the percentages may exceed 100% due to dual categorization. Participants with a missing baseline value are assumed to have a normal baseline value.

    Time frame: From Baseline (Day 1) and up to Day 38

  9. Monotherapy: Maximum Observed Plasma Drug Concentration (Cmax) of VH4524184

    Blood samples were collected at indicated time points for Pharmacokinetic (PK) analysis of VH4524184.

    Time frame: At Day 1 and Day 7

  10. Monotherapy: Time to Maximum Observed Plasma Drug Concentration (Tmax) of VH4524184

    Blood samples were collected at indicated time points for PK analysis of VH4524184.

    Time frame: At Day 1 and Day 7

  11. Monotherapy: Plasma Concentration of VH4524184 at Day 10

    Blood samples was collected at indicated time point for PK analysis of VH4524184.

    Time frame: At Day 10

  12. Monotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for maximum plasma HIV-1 RNA) were explored using an Emax non-linear mixed-effects model. The model parameters estimated were maximum response (Emax) which is defined as the maximum change (at infinite exposure) and EC50 which defines the PK parameter value that attains 50 percent (%) of the maximal effect

    Time frame: From Day 1 to Day 10

  13. Monotherapy: Number of Participants With Treatment-emergent Genotypic Resistance

    Plasma samples were collected to assess treatment emergent Genotypic Resistance.

    Time frame: At Baseline (Day 1) and Day 10

  14. Monotherapy: Number of Participants With Treatment-emergent Phenotypic Resistance

    Plasma samples were collected to assess treatment emergent Phenotypic Resistance.

    Time frame: At Baseline (Day 1) and Day 10

  15. Monotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10

    Blood samples were collected for assessment of T-cells subsets (CD4+ T-cells count) by flow cytometry at Day 10 compared to Baseline.

    Time frame: At Day 10 compared to Baseline (Day 1)

07

Results

Posted Jun 29, 2025

Participant flow

Monotherapy Period (Day 1 to Day 10)
Participant flow — Monotherapy Period (Day 1 to Day 10)
MilestoneVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Started6673
Completed6673
Not completed0000
Follow-Up Period(Day 11 to Day 38)
Participant flow — Follow-Up Period(Day 11 to Day 38)
MilestoneVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Started6673
Completed6673
Not completed0000

Outcome measures

PrimaryMonotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)

Plasma samples were collected for the quantitative analysis of plasma HIV-1 RNA. The maximum change from baseline was calculated by determining the largest change from baseline value across all assessment timepoints during the monotherapy period. This is identified by subtracting the lowest post-dose visit value up to Day 10 (inclusive) from the baseline value. The baseline was defined as the most recent pre-dose assessment with a valid, non-missing value, including measurements from any unscheduled visits.

Time frame:
At Day 10
Reported as:
Mean · Copies per milliliter (copies/mL)
Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)
Copies per milliliter (copies/mL)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)-1.17 ± 0.460-2.15 ± 0.254-2.31 ± 0.463-0.28 ± 0.370
SecondaryMonotherapy and Follow-up: Number of Participants With Any Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Any AEs = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 to Day 38
Reported as:
Count of participants · Participants
Monotherapy and Follow-up: Number of Participants With Any Adverse Event (AE)
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Monotherapy and Follow-up: Number of Participants With Any Adverse Event (AE)4652
SecondaryMonotherapy and Follow-up: Number of Participants With AEs by Severity

The severity was assessed using The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening and Grade 5 = Death.

Time frame:
Day 1 to Day 38
Reported as:
Count of participants · Participants
Monotherapy and Follow-up: Number of Participants With AEs by Severity
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Grade 13431
Grade 21221
Grade 30000
Grade 40000
Grade 50000
SecondaryMonotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation
Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation0000
SecondaryMonotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)

Blood samples were collected at the indicated timepoints.

Time frame:
At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Reported as:
Mean · International units per liter (IU/L)
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
International units per liter (IU/L)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
ALT, Baseline (Day 1)25.5 ± 15.3526.0 ± 9.2730.4 ± 20.8221.0 ± 7.21
ALT, Day 20.0 ± 4.201.3 ± 2.504.3 ± 11.700.0 ± 4.00
ALT, Day 42.2 ± 4.540.5 ± 4.420.0 ± 12.41-1.0 ± 1.00
ALT, Day 70.2 ± 3.25-3.5 ± 5.36-6.4 ± 14.39-1.3 ± 5.86
ALT, Day 104.5 ± 5.79-5.5 ± 5.82-6.1 ± 16.958.3 ± 16.50
ALT, Day 176.7 ± 15.10-7.0 ± 6.24-8.0 ± 13.99-3.0 ± 8.72
ALT, Day 24-1.7 ± 6.151.2 ± 12.22-8.6 ± 14.41-4.3 ± 4.51
ALT, Day 31-2.8 ± 10.310.2 ± 7.31-10.4 ± 11.84-5.0 ± 4.58
ALT, Day 38-2.8 ± 8.26-2.5 ± 9.16-13.0 ± 16.67-3.0 ± 5.57
AST, Baseline (Day 1)29.7 ± 24.6426.5 ± 11.4525.9 ± 8.7622.3 ± 11.68
AST, Day 2-1.3 ± 6.65-1.2 ± 4.962.6 ± 10.060.0 ± 3.46
AST, Day 42.2 ± 3.06-3.2 ± 9.02-2.9 ± 6.121.3 ± 3.06
AST, Day 7-0.3 ± 3.67-4.8 ± 6.97-4.9 ± 6.57-0.7 ± 4.73
AST, Day 109.7 ± 17.82-6.2 ± 8.47-4.7 ± 7.452.0 ± 11.79
AST, Day 1722.0 ± 47.41-9.0 ± 5.83-5.1 ± 7.36-1.3 ± 8.74
AST, Day 241.2 ± 8.01-4.3 ± 6.59-3.3 ± 6.73-4.0 ± 7.00
AST, Day 31-0.8 ± 6.30-3.0 ± 4.20-2.4 ± 6.45-3.0 ± 5.20
AST, Day 38-4.7 ± 14.05-4.7 ± 5.54-6.0 ± 9.360.3 ± 8.02
ALP, Baseline (Day 1)81.3 ± 32.5170.3 ± 15.7672.9 ± 10.06103.7 ± 56.00
ALP, Day 23.3 ± 9.142.5 ± 6.690.6 ± 3.267.3 ± 13.58
ALP, Day 42.5 ± 9.18-0.2 ± 3.132.9 ± 5.8413.3 ± 18.01
ALP, Day 73.7 ± 6.50-4.0 ± 3.63-2.6 ± 4.722.7 ± 15.82
ALP, Day 104.2 ± 3.92-1.7 ± 6.532.1 ± 3.895.7 ± 13.65
ALP, Day 174.5 ± 5.090.0 ± 3.740.9 ± 6.728.3 ± 4.93
ALP, Day 243.2 ± 2.86-0.2 ± 5.19-0.7 ± 6.80-1.3 ± 17.01
ALP, Day 315.2 ± 3.900.3 ± 12.600.1 ± 9.0120.3 ± 14.36
ALP, Day 384.5 ± 3.510.2 ± 14.33-0.6 ± 5.83-3.0 ± 21.17
SecondaryMonotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Bilirubin

Blood samples were collected at the indicated timepoints.

Time frame:
At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Reported as:
Mean · Micromoles per liter (μmol/L)
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Bilirubin
Micromoles per liter (μmol/L)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Baseline (Day 1)8.2935 ± 5.939145.6145 ± 3.219925.9117 ± 3.214108.0370 ± 5.75333
Day 21.0545 ± 3.030930.2565 ± 1.327871.1481 ± 1.75421-0.7410 ± 4.86174
Day 41.4820 ± 5.384370.8550 ± 2.932041.6856 ± 3.71694-3.2490 ± 5.08132
Day 7-1.5105 ± 4.257062.1660 ± 2.20230-0.8306 ± 2.63700-1.8813 ± 5.60653
Day 102.2515 ± 6.115410.7695 ± 3.538920.3176 ± 2.28020-3.0210 ± 3.16389
Day 170.7980 ± 7.477740.1368 ± 3.238630.4641 ± 3.390971.7670 ± 4.44052
Day 241.7100 ± 6.109270.2280 ± 3.655831.3436 ± 3.54789-0.5130 ± 2.68748
Day 31-0.2052 ± 7.415760.0285 ± 1.407680.3909 ± 2.628280.8550 ± 4.42292
Day 381.7100 ± 5.46665-0.1712 ± 3.595120.2931 ± 1.14163-3.1923 ± 3.60425
SecondaryMonotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Protein

Blood samples were collected at the indicated timepoints.

Time frame:
At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Reported as:
Mean · Grams per liter
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Protein
Grams per literVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Baseline (Day 1)76.5 ± 4.5575.5 ± 3.3977.1 ± 5.4970.0 ± 5.57
Day 22.8 ± 3.602.2 ± 3.310.7 ± 3.305.7 ± 1.53
Day 44.3 ± 4.371.5 ± 2.662.1 ± 2.972.0 ± 1.00
Day 72.0 ± 3.63-1.3 ± 2.34-1.9 ± 3.89-1.0 ± 1.00
Day 102.2 ± 2.40-0.7 ± 3.141.6 ± 2.640.3 ± 2.08
Day 171.2 ± 3.250.4 ± 2.300.1 ± 5.217.3 ± 4.16
Day 240.8 ± 3.060.3 ± 4.460.6 ± 4.432.0 ± 3.00
Day 310.4 ± 4.56-0.2 ± 5.23-0.9 ± 3.808.3 ± 4.51
Day 380.5 ± 2.26-1.3 ± 4.68-1.4 ± 4.352.0 ± 4.58
SecondaryMonotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: ALT, AST, ALP, Bilirubin

Liver panel parameters assessed were: ALT, AST, ALP, bilirubin. The parameters were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in grade relative to baseline grade.

Time frame:
From Baseline (Day 1) and up to Day 38
Reported as:
Count of participants · Participants
Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: ALT, AST, ALP, Bilirubin
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
ALT, Increase to Grade 10110
ALT, Increase to Grade 20000
ALT, Increase to Grade 30000
ALT, Increase to Grade 40000
AST, Increase to Grade 10010
AST, Increase to Grade 21000
AST, Increase to Grade 30000
AST, Increase to Grade 40000
ALP, Increase to Grade 11000
ALP, Increase to Grade 20000
ALP, Increase to Grade 30000
ALP, Increase to Grade 40000
Bilirubin, Increase to Grade 10000
Bilirubin, Increase to Grade 20000
Bilirubin, Increase to Grade 30000
Bilirubin, Increase to Grade 40000
SecondaryMonotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: Protein

Participants are categorized based on changes in their liver panel laboratory parameters (protein) to 'Low,' 'Normal,' or 'High,' unless there is no change in their initial category. Participants whose lab values remain unchanged (e.g., 'High' to 'High') or whose values return to normal are recorded in the 'To Normal or No Change' category. Participants may be counted in both the 'To Low' and 'To High' categories if their values fluctuate between these states. As a result, the percentages may exceed 100% due to dual categorization. Participants with a missing baseline value are assumed to have a normal baseline value.

Time frame:
From Baseline (Day 1) and up to Day 38
Reported as:
Count of participants · Participants
Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: Protein
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
To Low0000
To Normal or No Change4452
To High2221
SecondaryMonotherapy: Maximum Observed Plasma Drug Concentration (Cmax) of VH4524184

Blood samples were collected at indicated time points for Pharmacokinetic (PK) analysis of VH4524184.

Time frame:
At Day 1 and Day 7
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Monotherapy: Maximum Observed Plasma Drug Concentration (Cmax) of VH4524184
Nanogram per milliliter (ng/mL)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Day 11332.57 ± 16.786173.61 ± 30.7123589.70 ± 32.39
Day 71488.59 ± 32.067112.60 ± 16.5923069.92 ± 45.77
SecondaryMonotherapy: Time to Maximum Observed Plasma Drug Concentration (Tmax) of VH4524184

Blood samples were collected at indicated time points for PK analysis of VH4524184.

Time frame:
At Day 1 and Day 7
Reported as:
Median · hours
Monotherapy: Time to Maximum Observed Plasma Drug Concentration (Tmax) of VH4524184
hoursVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Day 13.13 (1.0 to 5.0)4.00 (2.0 to 5.0)2.00 (1.0 to 5.0)
Day 74.00 (0.5 to 5.1)4.49 (1.0 to 6.0)2.13 (1.0 to 4.0)
SecondaryMonotherapy: Plasma Concentration of VH4524184 at Day 10

Blood samples was collected at indicated time point for PK analysis of VH4524184.

Time frame:
At Day 10
Reported as:
Mean · ng/mL
Monotherapy: Plasma Concentration of VH4524184 at Day 10
ng/mLVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Monotherapy: Plasma Concentration of VH4524184 at Day 10127.5 ± 75.59523.5 ± 324.501328.3 ± 486.99
SecondaryMonotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for maximum plasma HIV-1 RNA) were explored using an Emax non-linear mixed-effects model. The model parameters estimated were maximum response (Emax) which is defined as the maximum change (at infinite exposure) and EC50 which defines the PK parameter value that attains 50 percent (%) of the maximal effect

Time frame:
From Day 1 to Day 10
Reported as:
Mean · Log10 copies/mL
Monotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10
Log10 copies/mLVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Monotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10-1.17 ± 0.460-2.15 ± 0.254-2.31 ± 0.463
Statistical analysis
  • VH4524184 Dose 1 vs VH4524184 Dose 2 vs VH4524184 Dose 3 · Emax: -2.69
  • VH4524184 Dose 1 vs VH4524184 Dose 2 vs VH4524184 Dose 3 · Ec50: 1.88
SecondaryMonotherapy: Number of Participants With Treatment-emergent Genotypic Resistance

Plasma samples were collected to assess treatment emergent Genotypic Resistance.

Time frame:
At Baseline (Day 1) and Day 10
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With Treatment-emergent Genotypic Resistance
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Day 1000
Day 10000
SecondaryMonotherapy: Number of Participants With Treatment-emergent Phenotypic Resistance

Plasma samples were collected to assess treatment emergent Phenotypic Resistance.

Time frame:
At Baseline (Day 1) and Day 10
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With Treatment-emergent Phenotypic Resistance
ParticipantsVH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3
Day 1000
Day 10000
SecondaryMonotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10

Blood samples were collected for assessment of T-cells subsets (CD4+ T-cells count) by flow cytometry at Day 10 compared to Baseline.

Time frame:
At Day 10 compared to Baseline (Day 1)
Reported as:
Mean · CD4+ million cells per Liter (10^6/L)
Monotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10
CD4+ million cells per Liter (10^6/L)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3Placebo
Monotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10131.333 ± 98.447368.667 ± 122.119147.000 ± 45.909363.667 ± 216.1512

Adverse events

Collected over Serious AEs (SAEs) and Non-serious AEs were assessed from Day 1 until the final visit in the Follow-up Period (at Day 38). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VH4524184 Dose 1_Monotherapy0/6 (0%)0/6 (0%)2/6 (33.3%)
VH4524184 Dose 2_Monotherapy0/6 (0%)0/6 (0%)3/6 (50%)
VH4524184 Dose 3_Monotherapy0/7 (0%)0/7 (0%)3/7 (42.9%)
Placebo_Monotherapy0/3 (0%)0/3 (0%)2/3 (66.7%)
VH4524184 Dose 1_Follow-up0/6 (0%)0/6 (0%)4/6 (66.7%)
VH4524184 Dose 2_Follow-up0/6 (0%)0/6 (0%)5/6 (83.3%)
VH4524184 Dose 3_Follow-up0/7 (0%)0/7 (0%)4/7 (57.1%)
Placebo_Follow-up0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventVH4524184 Dose 1_MonotherapyVH4524184 Dose 2_MonotherapyVH4524184 Dose 3_MonotherapyPlacebo_MonotherapyVH4524184 Dose 1_Follow-upVH4524184 Dose 2_Follow-upVH4524184 Dose 3_Follow-upPlacebo_Follow-up
HeadacheNervous system disorders0/60/61/70/30/60/61/72/3
DiarrhoeaGastrointestinal disorders1/60/60/70/30/60/61/71/3
DyspepsiaGastrointestinal disorders0/60/60/71/31/60/61/70/3
NauseaGastrointestinal disorders0/60/61/70/30/60/60/71/3
Upper respiratory tract infectionInfections and infestations0/60/60/71/31/60/60/70/3
Blood pressure increasedInvestigations0/60/60/71/30/60/60/70/3
GastroenteritisInfections and infestations0/60/60/70/30/61/60/71/3
VomitingGastrointestinal disorders0/61/61/70/30/60/60/70/3
FatigueGeneral disorders0/61/60/70/30/60/60/70/3
Influenza like illnessGeneral disorders0/60/61/70/31/60/61/70/3

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3PlaceboTotal
Mean34.2 ± 10.6136.7 ± 16.1833.9 ± 12.5229.3 ± 3.7934.1 ± 11.85
Sex: Female, Male
Sex: Female, Male(Participants)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3PlaceboTotal
Female02103
Male646319
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VH4524184 Dose 1VH4524184 Dose 2VH4524184 Dose 3PlaceboTotal
All Other Races667322
08

Study locations

17 sites
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    West Hollywood, California 90046, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Buenos Aires, C1202, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1405CKC, Argentina
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Milan, 20162, Italy
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08026, Spain
  • GSK Investigational Site
    Elche Alicante, 03203, Spain
  • GSK Investigational Site
    Madrid, 28020, Spain
  • GSK Investigational Site
    Murcia, 30003, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2024, 4 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 4 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Feb 7, 2024
Primary completionActual
Jun 12, 2024
CompletionActual
Jun 12, 2024
Results first posted
Jun 29, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06214052
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Feb 7, 2024
Primary completion
Jun 12, 2024
Completion
Jun 12, 2024
Results posted
Jun 29, 2025
Last update
Jun 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion